SALUD. La Comunidad de Madrid participa en "MonarchE", un ensayo clínico de un medicamento contra el cáncer de mama salud, cáncer de mama, medicamentos, MonarchE

SALUD. El ensayo clínico fase 3 MonarchE, donde participa la Comunidad de Madrid, demuestra que añadir abemaciclib a la hormonoterapia reduce significativamente el riesgo de recaída en pacientes de alto riesgo. www.cronicadelhenares.com/2025/10/salu... #MonarchE #CancerDeMama #Abemaciclib #Oncología

In The Lancet Regional Health – Europe: important real-world insights into the prevalence and prognosis of pts with early ER+/HER2- breast cancer who may be eligible for adjuvant CDK4/6 inhibitors: #monarchE and #NATALEE compared to #PANTHER trial #GBG53
www.sciencedirect.com/science/arti...

Abemaciclib Plus Endocrine Therapy Improves Survival in High-Risk HR+, HER2– Early Breast Cancer | Docwire News Verzenio + ET improves OS, IDFS, and DRFS in high-risk HR+, HER2– early breast cancer in the monarchE trial.

Phase 3 #monarchE: Abemaciclib (Verzenio) + endocrine therapy significantly improved OS vs ET alone in high-risk HR+/HER2– early breast cancer.

7-yr data: sustained IDFS & DRFS benefit, reinforcing SOC role.

🔗 www.docwirenews.com/post/abemaci... @erikahamilton9.bsky.social